Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1011320220140020101
Journal of Pharmacoepidemiology and Risk Management
2022 Volume.14 No. 2 p.101 ~ p.108
Systematic Review for Remdesivir Use in Pediatric Patients under 3.5 kg with COVID-19
Cho Won-Bean

Lee Na-Yoon
Ah Young-Mi
Abstract
Objective: We aimed to identify the safety and efficacy of remdesivir in pediatric COVID-19 patients less than 3.5 kg by systematic review.

Methods: We conducted a literature search using MEDLINE, EMBASE, CENTRAL, and Google scholar based on keywords about remdesivir and neonates or infants. We also did a hand search using bibliography information of related literature. The literature reporting remdesivir use for COVID-19 treatment in pediatric patients under 3.5 kg were selected. Two researchers performed study selection and data extraction. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to evaluate the quality of the included literature.

Results: Finally, 7 out of 8 patients were selected among 1,478 studies searched. Mechanical ventilation was applied to all cases, remdesivir were administered for 4 or 10 days using the normal dose or half of the normal dose. In 7 out of 8 cases, the condition of the child was reported to have improved after remdesivir use, and remdesivir associated adverse drug events were not identified.

Conclusion: Considering the clinical outcomes of case reports about remdesivir use in pediatric patients less than 3.5 kg in this study, remdesivir might be one of treatment strategies for pediatric patients less than 3.5 kg requiring mechanical ventilation. However, additional studies are needed to confirm the evidence of remdesivir for pediatric patients.
KEYWORD
Remdesivir, SARS-CoV2, COVID-19, Systematic review, Pediatric, Neonat
FullTexts / Linksout information
Listed journal information